Jonášová A
I. interní klinika - klinika hermatologie 1. lékařské fakulty UK a VFVN Praha.
Vnitr Lek. 2013 Jul;59(7):635-40.
Myelodysplastic syndrome is one of the most common hematology diseases in the age over the 60. Until recently the therapy of this disease was frustrating and often based only on supportive care. The last decade witnessed the emergence of promising drugs that represent a major breakthrough in the therapy and interest of decoding of the pathogenesis of this disease. In our work we summarize the evolution of MDS therapy with accent on the new drugs contribution.
骨髓增生异常综合征是60岁以上人群中最常见的血液学疾病之一。直到最近，这种疾病的治疗一直令人沮丧，且往往仅基于支持性治疗。过去十年见证了一些有前景的药物的出现，这些药物代表了治疗方面的重大突破以及对该疾病发病机制解码的关注。在我们的工作中，我们总结了骨髓增生异常综合征治疗的演变，重点强调新药的贡献。
